Clinical Rheumatology

, Volume 33, Issue 2, pp 215–220 | Cite as

Serum galectin-3 level in systemic sclerosis

  • Suleyman Serdar KocaEmail author
  • Fatma Akbas
  • Metin Ozgen
  • Servet Yolbas
  • Nevin Ilhan
  • Baris Gundogdu
  • Ahmet Isik
Original Article


Systemic sclerosis (SSc) is an autoimmune disease of unknown etiology characterized by progressive fibrosis. Activated fibroblasts are mainly responsible for fibrosis in SSc. Galectin-3, a β-galactoside-binding lectin, plays many important regulatory roles in both physiological and pathological processes including proliferation, apoptosis, inflammation, and fibrosis. The purpose of this study was to assess the serum galectin-3 levels in patients with SSc. Thirty-seven SSc patients, 23 systemic lupus erythematosus (SLE) patients (serving as patient control group), and 28 healthy volunteers were enrolled in this study. Disease activity and severity scores were detected with Valentini disease activity index and Medsger disease severity scale in the SSc group and SLE disease activity index and Systemic Lupus International Collaborating Clinics/American College of Rheumatology damage index in the SLE group. The serum levels of galectin-3, vascular endothelial growth factor, transforming growth factor-β, and interleukin-6 were determined. Compared to the control group, the galectin-3 levels were higher in the SSc and SLE groups. The galectin-3 levels were not correlated with the disease activity and severity indexes in both patient groups. But, the serum galectin-3 levels were higher in the active SSc and SLE subgroups than in the inactive SSc (4.6 ± 5.8 vs. 1.3 ± 1.1 ng/ml, p = 0.015) and SLE (17.4 ± 11.3 vs. 6.5 ± 8.9 ng/ml, p = 0.019) subgroups. These results suggest that galectin-3, which is associated with fibrosis and inflammation by previous studies, may be a prominent biomarker of disease activity in SSc.


Disease activity Galectin-3 Systemic sclerosis 





  1. 1.
    Gabrielli A, Avvedimento EV, Krieg T (2009) Scleroderma. N Engl J Med 360(19):1989–2003PubMedCrossRefGoogle Scholar
  2. 2.
    Rabquer BJ, Koch AE (2012) Angiogenesis and vasculopathy in systemic sclerosis: evolving concepts. Curr Rheumatol Rep 14(1):56–63PubMedCrossRefGoogle Scholar
  3. 3.
    LeRoy EC, Black C, Fleischmajer R, Jablonska S, Krieg T, Medsger TA Jr, Rowell N, Wollheim F (1988) Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. J Rheumatol 15(2):202–5PubMedGoogle Scholar
  4. 4.
    LeRoy EC (1974) Increased collagen synthesis by scleroderma skin fibroblasts in vitro: a possible defect in the regulation or activation of the scleroderma fibroblast. J Clin Invest 54(4):880–9PubMedCentralPubMedCrossRefGoogle Scholar
  5. 5.
    Henderson NC, Sethi T (2009) The regulation of inflammation by galectin-3. Immunol Rev 230(1):160–71PubMedCrossRefGoogle Scholar
  6. 6.
    Barondes SH, Cooper DN, Gitt MA, Leffler H (1994) Galectins. Structure and function of a large family of animal lectins. J Biol Chem 269(33):20807–10PubMedGoogle Scholar
  7. 7.
    Ho MK, Springer TA (1982) Mac-2, a novel 32,000 Mr mouse macrophage subpopulation-specific antigen defined by monoclonal antibodies. J Immunol 128(3):1221–8PubMedGoogle Scholar
  8. 8.
    Hirabayashi J, Hashidate T, Arata Y, Nishi N, Nakamura T, Hirashima M, Urashima T, Oka T, Futai M, Muller WE, Yagi F, Kasai K (2002) Oligosaccharide specificity of galectins: a search by frontal affinity chromatography. Biochim Biophys Acta 1572(2–3):232–54PubMedCrossRefGoogle Scholar
  9. 9.
    Dhirapong A, Lleo A, Leung P, Gershwin ME, Liu FT (2009) The immunological potential of galectin-1 and -3. Autoimmun Rev 8(5):360–3PubMedCrossRefGoogle Scholar
  10. 10.
    Nishi Y, Sano H, Kawashima T, Okada T, Kuroda T, Kikkawa K, Kawashima S, Tanabe M, Goto T, Matsuzawa Y, Matsumura R, Tomioka H, Liu FT, Shirai K (2007) Role of galectin-3 in human pulmonary fibrosis. Allergol Int 56(1):57–65PubMedCrossRefGoogle Scholar
  11. 11.
    Henderson NC, Mackinnon AC, Farnworth SL, Poirier F, Russo FP, Iredale JP, Haslett C, Simpson KJ, Sethi T (2006) Galectin-3 regulates myofibroblast activation and hepatic fibrosis. Proc Natl Acad Sci 103(13):5060–5PubMedCrossRefGoogle Scholar
  12. 12.
    Hochberg MC (1997) Update of the 1982 American College of Rheumatology Revised Criteria for Classification of Systemic Lupus Erythematosus. Arthritis Rheum 40:1725PubMedCrossRefGoogle Scholar
  13. 13.
    Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee (1980) Preliminary criteria for the classification of systemic sclerosis (scleroderma). Arthritis Rheum 23(5):581–90CrossRefGoogle Scholar
  14. 14.
    Valentini G, Della Rossa A, Bombardieri S, Bencivelli W, Silman AJ, D'Angelo S, Cerinic MM, Belch JF, Black CM, Bruhlmann P, Czirják L, De Luca A, Drosos AA, Ferri C, Gabrielli A, Giacomelli R, Hayem G, Inanc M, McHugh NJ, Nielsen H, Rosada M, Scorza R, Stork J, Sysa A, van den Hoogen FH, Vlachoyiannopoulos PJ (2001) European multicentre study to define disease activity criteria for systemic sclerosis. II. Identification of disease activity variables and development of preliminary activity indexes. Ann Rheum Dis 60(6):592–8PubMedCrossRefGoogle Scholar
  15. 15.
    Medsger TA Jr, Silman AJ, Steen VD, Black CM, Akesson A, Bacon PA, Harris CA, Jablonska S, Jayson MI, Jimenez SA, Krieg T, Leroy EC, Maddison PJ, Russell ML, Schachter RK, Wollheim FA, Zacharaie H (1999) A disease severity scale for systemic sclerosis: development and testing. J Rheumatol 26(10):2159–67PubMedGoogle Scholar
  16. 16.
    Bombardier C, Gladman DD, Urowitz MB, Caron D, Chang CH (1992) Derivation of the SLEDAI. A disease activity index for lupus patients. The Committee on Prognosis Studies in SLE. Arthritis Rheum 35(6):630–40PubMedCrossRefGoogle Scholar
  17. 17.
    Gladman D, Ginzler E, Goldsmith C, Fortin P, Liang M, Urowitz M, Bacon P, Bombardieri S, Hanly J, Hay E, Isenberg D, Jones J, Kalunian K, Maddison P, Nived O, Petri M, Richter M, Sanchez-Guerrero J, Snaith M, Sturfelt G, Symmons D, Zoma A (1996) The development and initial validation of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology damage index for systemic lupus erythematosus. Arthritis Rheum 39(3):363–9PubMedCrossRefGoogle Scholar
  18. 18.
    Abrahamowicz M, Fortin PR, du Berger R, Nayak V, Neville C, Liang MH (1998) The relationship between disease activity and expert physician's decision to start major treatment in active systemic lupus erythematosus: a decision aid for development of entry criteria for clinical trials. J Rheumatol 25(2):277–84PubMedGoogle Scholar
  19. 19.
    Castro SV, Jimenez SA (2010) Biomarkers in systemic sclerosis. Biomark Med 4(1):133–47PubMedCentralPubMedCrossRefGoogle Scholar
  20. 20.
    Moinzadeh P, Denton CP, Abraham D, Ong V, Hunzelmann N, Eckes B, Krieg T (2012) Biomarkers for skin involvement and fibrotic activity in scleroderma. J Eur Acad Dermatol Venereol 26(3):267–76PubMedCrossRefGoogle Scholar
  21. 21.
    Abraham DJ, Krieg T, Distler J, Distler O (2009) Overview of pathogenesis of systemic sclerosis. Rheumatology 48:iii3–iii7PubMedCrossRefGoogle Scholar
  22. 22.
    Shi-Wen X, Denton CP, Dashwood MR, Holmes AM, Bou-Gharios G, Pearson JD, Black CM, Abraham DJ (2001) Fibroblast matrix gene expression and connective tissue remodeling: role of endothelin-1. J Invest Dermatol 116(3):417–25PubMedCrossRefGoogle Scholar
  23. 23.
    Dragomir AC, Sun R, Mishin V, Hall LB, Laskin JD, Laskin DL (2012) Role of galectin-3 in acetaminophen-induced hepatotoxicity and inflammatory mediator production. Toxicol Sci 127(2):609–19PubMedCrossRefGoogle Scholar
  24. 24.
    Calvier L, Miana M, Reboul P, Cachofeiro V, Martinez-Martinez E, de Boer RA, Poirier F, Lacolley P, Zannad F, Rossignol P, López-Andrés N (2013) Galectin-3 mediates aldosterone-induced vascular fibrosis. Arterioscler Thromb Vasc Biol 33(1):67–75PubMedCrossRefGoogle Scholar
  25. 25.
    Colnot C, Ripoche MA, Milon G, Montagutelli X, Crocker PR, Poirier F (1998) Maintenance of granulocyte numbers during acute peritonitis is defective in galectin-3-null mutant mice. Immunology 94(3):290–6PubMedCrossRefGoogle Scholar
  26. 26.
    Hsu DK, Yang RY, Pan Z, Yu L, Salomon DR, Fung-Leung WP, Liu FT (2000) Targeted disruption of the galectin-3 gene results in attenuated peritoneal inflammatory responses. Am J Pathol 156(3):1073–83PubMedCrossRefGoogle Scholar
  27. 27.
    Nieminen J, St-Pierre C, Bhaumik P, Poirier F, Sato S (2008) Role of galectin-3 in leukocyte recruitment in a murine model of lung infection by Streptococcus pneumoniae. J Immunol 180(4):2466–73PubMedGoogle Scholar
  28. 28.
    Ohshima S, Kuchen S, Seemayer CA, Kyburz D, Hirt A, Klinzing S, Michel BA, Gay RE, Liu FT, Gay S, Neidhart M (2003) Galectin 3 and its binding protein in rheumatoid arthritis. Arthritis Rheum 48(10):2788–95PubMedCrossRefGoogle Scholar
  29. 29.
    Lee YJ, Kang SW, Song JK, Park JJ, Bae YD, Lee EY, Lee EB, Song YW (2007) Serum galectin-3 and galectin-3 binding protein levels in Behçet's disease and their association with disease activity. Clin Exp Rheumatol 25(4 Suppl 45):S41–5PubMedGoogle Scholar
  30. 30.
    Kang EH, Moon KC, Lee EY, Lee YJ, Lee EB, Ahn C, Song YW (2009) Renal expression of galectin-3 in systemic lupus erythematosus patients with nephritis. Lupus 18(1):22–8PubMedCrossRefGoogle Scholar
  31. 31.
    Okamura DM, Pasichnyk K, Lopez-Guisa JM, Collins S, Hsu DK, Liu FT, Eddy AA (2011) Galectin-3 preserves renal tubules and modulates extracellular matrix remodeling in progressive fibrosis. Am J Physiol Renal Physiol 300(1):F245–53PubMedCrossRefGoogle Scholar
  32. 32.
    Mackinnon AC, Gibbons MA, Farnworth SL, Leffler H, Nilsson UJ, Delaine T, Simpson AJ, Forbes SJ, Hirani N, Gauldie J, Sethi T (2012) Regulation of transforming growth factor-β1-driven lung fibrosis by galectin-3. Am J Respir Crit Care Med 185(5):537–46PubMedCrossRefGoogle Scholar
  33. 33.
    Taniguchi T, Asano Y, Akamata K, Noda S, Masui Y, Yamada D, Takahashi T, Ichimura Y, Toyama T, Tamaki Z, Tada Y, Sugaya M, Kadono T, Sato S (2012) Serum levels of galectin-3: possible association with fibrosis, aberrant angiogenesis, and immune activation in patients with systemic sclerosis. J Rheumatol 39(3):539–44PubMedCrossRefGoogle Scholar
  34. 34.
    Hudson M, Steele R, Canadian Scleroderma Research Group (CSRG), Baron M (2007) Update on indices of disease activity in systemic sclerosis. Semin Arthritis Rheum 37(2):93–8PubMedCrossRefGoogle Scholar
  35. 35.
    Medsger TA Jr (2003) Natural history of systemic sclerosis and the assessment of disease activity, severity, functional status, and psycho logic well-being. Rheum Dis Clin North Am 29(2):255–73PubMedCrossRefGoogle Scholar
  36. 36.
    Valentini G, Silman AJ, Veale D (2003) Assessment of disease activity. Clin Exp Rheumatol 21:S39–41PubMedGoogle Scholar
  37. 37.
    Clements PJ (1995) Measuring disease activity and severity in scleroderma. Curr Opin Rheumatol 7(6):517–21PubMedCrossRefGoogle Scholar
  38. 38.
    Hummers LK (2010) The current state of biomarkers in systemic sclerosis. Curr Rheumatol Rep 12(1):34–9PubMedCentralPubMedCrossRefGoogle Scholar

Copyright information

© Clinical Rheumatology 2013

Authors and Affiliations

  • Suleyman Serdar Koca
    • 1
    Email author
  • Fatma Akbas
    • 2
  • Metin Ozgen
    • 1
  • Servet Yolbas
    • 1
  • Nevin Ilhan
    • 3
  • Baris Gundogdu
    • 1
  • Ahmet Isik
    • 1
  1. 1.Department of Rheumatology, Faculty of MedicineFirat UniversityElazigTurkey
  2. 2.Department of Internal Medicine, Faculty of MedicineFirat UniversityElazigTurkey
  3. 3.Department of Biochemistry, Faculty of MedicineFirat UniversityElazigTurkey

Personalised recommendations